DOP2022000268A - Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso - Google Patents

Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso

Info

Publication number
DOP2022000268A
DOP2022000268A DO2022000268A DO2022000268A DOP2022000268A DO P2022000268 A DOP2022000268 A DO P2022000268A DO 2022000268 A DO2022000268 A DO 2022000268A DO 2022000268 A DO2022000268 A DO 2022000268A DO P2022000268 A DOP2022000268 A DO P2022000268A
Authority
DO
Dominican Republic
Prior art keywords
hlai
neoantigen
classical
complex
methods
Prior art date
Application number
DO2022000268A
Other languages
English (en)
Inventor
Weidanz Jon
Upchurch-Ange Katherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2022000268A publication Critical patent/DOP2022000268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan anticuerpos que se unen selectivamente a un complejo que comprende un HLA–I no clásico (por ejemplo, HLA–E) y un neoantígeno que tiene dominios variables de la cadena pesada (VH), dominios variables de la cadena ligera (VL) y regiones determinantes de complementariedad (CDR) como se divulga en la presente, así como métodos y usos de estos.
DO2022000268A 2020-06-01 2022-11-28 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso DOP2022000268A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032747P 2020-06-01 2020-06-01
US17/199,205 US11359023B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
PCT/US2021/035290 WO2021247607A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (1)

Publication Number Publication Date
DOP2022000268A true DOP2022000268A (es) 2023-01-15

Family

ID=75495114

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000268A DOP2022000268A (es) 2020-06-01 2022-11-28 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso

Country Status (19)

Country Link
US (4) US10981996B1 (es)
EP (1) EP4157882A4 (es)
JP (1) JP2023530036A (es)
KR (1) KR20230019468A (es)
CN (1) CN116367865A (es)
AR (1) AR122501A1 (es)
AU (1) AU2021284275A1 (es)
BR (1) BR112022024275A2 (es)
CA (1) CA3174090A1 (es)
CL (1) CL2022003336A1 (es)
CO (1) CO2022018426A2 (es)
CR (1) CR20220652A (es)
DO (1) DOP2022000268A (es)
EC (1) ECSP22097197A (es)
IL (1) IL298020A (es)
MX (1) MX2022015114A (es)
PE (1) PE20230306A1 (es)
TW (1) TW202235439A (es)
WO (1) WO2021247607A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019309948A1 (en) * 2018-07-23 2021-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
TW202346367A (zh) * 2022-04-08 2023-12-01 美商提聖納醫療公司 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體、抗ｐｄ１或抗ｐｄ－ｌ１抗體、及／或抗ｃｄ４７抗體之組合療法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2998320B1 (en) 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2015095392A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
JP2017528418A (ja) 2014-06-20 2017-09-28 バイオアライアンス コマンディテール フェンノートシャップ 抗葉酸受容体アルファ（ｆｒａ）抗体−薬物コンジュゲート及びその使用方法
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
SG11201705496SA (en) 2015-01-08 2017-08-30 Genmab As Bispecific antibodies against cd3 and cd20
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3573997A4 (en) 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
EP3755371A4 (en) 2018-02-23 2021-11-24 Abexxa Biologics, Inc. ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN
AU2019309948A1 (en) 2018-07-23 2021-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Also Published As

Publication number Publication date
EP4157882A4 (en) 2024-06-26
KR20230019468A (ko) 2023-02-08
CN116367865A (zh) 2023-06-30
US11359023B2 (en) 2022-06-14
BR112022024275A2 (pt) 2023-05-02
AR122501A1 (es) 2022-09-14
PE20230306A1 (es) 2023-02-13
CA3174090A1 (en) 2021-12-09
JP2023530036A (ja) 2023-07-12
CR20220652A (es) 2023-07-03
US20240026007A1 (en) 2024-01-25
EP4157882A1 (en) 2023-04-05
TW202235439A (zh) 2022-09-16
WO2021247607A1 (en) 2021-12-09
CL2022003336A1 (es) 2023-06-23
MX2022015114A (es) 2023-03-24
US10981996B1 (en) 2021-04-20
US20210371532A1 (en) 2021-12-02
CO2022018426A2 (es) 2022-12-30
US20220332831A1 (en) 2022-10-20
IL298020A (en) 2023-01-01
ECSP22097197A (es) 2023-02-28
AU2021284275A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
ECSP22097197A (es) Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso
ECSP22097203A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
AR122502A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
CO2022008407A2 (es) Anticuerpos específicos para cd47, pd–l1 y sus usos
CO2017005240A2 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CY1119335T1 (el) Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
PE20171244A1 (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit)
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
CL2021001628A1 (es) Anticuerpo humanizado anti-pd-1 humana
CR20110566A (es) Inmunoconjugados de antimesotelina y usos de los mismos
EA201070888A1 (ru) Антитела и их производные
CO2022013898A2 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
MX2021001254A (es) Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
BR112021020677A2 (pt) Anticorpos contra receptores de antígeno quimérico derivados de 4g7
CO2023004381A2 (es) Anticuerpos cd1a y su uso
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
AR122257A2 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
AR122983A1 (es) ANTICUERPOS ANTI-a4b7